AbbVie (NYSE:ABBV) updated its FY20 earnings guidance on Friday. The company provided EPS guidance of $9.61-9.71 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.78. AbbVie also updated its FY 2020
Pre-Market guidance to 9.61-9.71 EPS.
A number of research analysts have commented on the stock. ValuEngine downgraded shares of AbbVie from a hold rating to a sell rating in a research report on Tuesday, January 28th. Citigroup raised their price target on shares of AbbVie from $90.00 to $98.00 and gave the company a buy rating in a report on Wednesday, November 20th. Bank of America cut shares of AbbVie from a buy rating to a neutral rating in a report on Friday, January 3rd. Mizuho started coverage on shares of AbbVie in a report on Wednesday. They issued a buy rating and a $96.00 price target on the stock. Finally, Royal Bank of Canada restated a hold rating and issued a $86.00 price target on shares of AbbVie in a report on Thursday, January 23rd. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $87.13.
ABBV stock opened at $90.69 on Friday. The firm has a 50 day moving average of $87.30 and a 200 day moving average of $78.34. The stock has a market capitalization of $128.11 billion, a PE ratio of 41.79, a price-to-earnings-growth ratio of 2.06 and a beta of 0.96. AbbVie has a 52 week low of $62.66 and a 52 week high of $91.99.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.